Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan
A Registry Study to Describe the Implications of Therapeutic Management of Etanercept in Patients With Rheumatoid Arthritis
Sponsor: Pfizer
This observational or N/A phase trial investigates Rheumatoid Arthritis and is currently completed. Pfizer leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed
-
Sep 2025 — Dec 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Changhua, Taiwan , Dalin, Taiwan , Guishanli, Taiwan , Hualien City, Taiwan , Kaohsiung City, Taiwan , Keelung, Taiwan , Lukang Zhen, Taiwan , Niao Sung Hsiang, Taiwan , Putz, Taiwan , Taichung, Taiwan and 4 more locations